JPWO2019217922A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019217922A5 JPWO2019217922A5 JP2020563659A JP2020563659A JPWO2019217922A5 JP WO2019217922 A5 JPWO2019217922 A5 JP WO2019217922A5 JP 2020563659 A JP2020563659 A JP 2020563659A JP 2020563659 A JP2020563659 A JP 2020563659A JP WO2019217922 A5 JPWO2019217922 A5 JP WO2019217922A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- cmv
- acid sequences
- vaccine composition
- expression system
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000701022 Cytomegalovirus Species 0.000 claims 15
- 239000000427 antigen Substances 0.000 claims 14
- 102000036639 antigens Human genes 0.000 claims 14
- 108091007433 antigens Proteins 0.000 claims 14
- 230000035772 mutation Effects 0.000 claims 11
- 150000007523 nucleic acids Chemical group 0.000 claims 11
- 230000000890 antigenic effect Effects 0.000 claims 9
- 229960005486 vaccine Drugs 0.000 claims 8
- 239000012634 fragment Substances 0.000 claims 7
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 230000037431 insertion Effects 0.000 claims 3
- 238000003780 insertion Methods 0.000 claims 3
- 241001212582 Ancara Species 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 229940104302 cytosine Drugs 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 230000002068 genetic effect Effects 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 108020004705 Codon Proteins 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000005457 optimization Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862670656P | 2018-05-11 | 2018-05-11 | |
| US62/670,656 | 2018-05-11 | ||
| PCT/US2019/031866 WO2019217922A1 (en) | 2018-05-11 | 2019-05-10 | Genetically modified recombinant vaccinia ankara (rmva) vaccines of improved stability and methods of preparation thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021523712A JP2021523712A (ja) | 2021-09-09 |
| JPWO2019217922A5 true JPWO2019217922A5 (https=) | 2022-05-18 |
| JP2021523712A5 JP2021523712A5 (https=) | 2022-05-18 |
Family
ID=68467105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020563659A Pending JP2021523712A (ja) | 2018-05-11 | 2019-05-10 | 安定性が改善された遺伝子組み換え組換えワクシニアアンカラ（ｒｍｖａ）ワクチン及びその調製方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12054736B2 (https=) |
| EP (1) | EP3790578A4 (https=) |
| JP (1) | JP2021523712A (https=) |
| CN (1) | CN112512568A (https=) |
| WO (1) | WO2019217922A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8580276B2 (en) | 2009-06-05 | 2013-11-12 | City Of Hope | Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof |
| EP3529353A4 (en) | 2016-10-19 | 2020-05-13 | City of Hope | USE OF TRIPLEX-CMV VACCINE IN CAR-T-CELL THERAPY |
| KR20250005247A (ko) | 2022-04-13 | 2025-01-09 | 시티 오브 호프 | Cmv-hiv 특이적 키메라 항원 수용체 t 세포 |
| WO2025184598A1 (en) * | 2024-03-01 | 2025-09-04 | City Of Hope | Stable and immunogenic cmv vaccine |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6835383B2 (en) | 2000-03-23 | 2004-12-28 | City Of Hope | Protein kinase deficient, immunologically active CMVpp65 mutants |
| CN102703393A (zh) | 2002-05-16 | 2012-10-03 | 巴法里安诺迪克有限公司 | 表达插入痘病毒基因组中的同源基因的重组痘病毒 |
| US7501127B2 (en) * | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
| US7163685B2 (en) | 2003-04-16 | 2007-01-16 | City Of Hope | Human cytomegalovirus antigens expressed in MVA and methods of use |
| US8580276B2 (en) * | 2009-06-05 | 2013-11-12 | City Of Hope | Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof |
| US8326547B2 (en) * | 2009-10-07 | 2012-12-04 | Nanjingjinsirui Science & Technology Biology Corp. | Method of sequence optimization for improved recombinant protein expression using a particle swarm optimization algorithm |
| WO2011047324A1 (en) | 2009-10-16 | 2011-04-21 | The U.S.A. As Represented By The Secretary , Department Of Health And Human Services . | Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites |
| JP2013544504A (ja) | 2010-10-11 | 2013-12-19 | ノバルティス アーゲー | 抗原送達プラットフォーム |
| DK2877580T3 (en) | 2012-07-27 | 2019-04-23 | Hope City | VAT VACCINE TO DELIVER A UL128 COMPLEX AND PREVENT CMV INFECTION |
| WO2018075813A1 (en) * | 2016-10-19 | 2018-04-26 | City Of Hope | Use of endogenous viral vaccine in chimeric antigen receptor t cell therapy |
-
2019
- 2019-05-10 EP EP19800357.6A patent/EP3790578A4/en not_active Withdrawn
- 2019-05-10 JP JP2020563659A patent/JP2021523712A/ja active Pending
- 2019-05-10 WO PCT/US2019/031866 patent/WO2019217922A1/en not_active Ceased
- 2019-05-10 CN CN201980046532.XA patent/CN112512568A/zh active Pending
-
2020
- 2020-11-11 US US17/095,300 patent/US12054736B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021523712A5 (https=) | ||
| Fisher et al. | Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis | |
| JP2641688B2 (ja) | ヘルペスウィルスベクターを使用する蛋白質の製造方法 | |
| RU2219241C2 (ru) | Дефектный рекомбинантный аденовирусный вектор (варианты) | |
| RU2019119272A (ru) | Вирусная доставка неоантигенов | |
| JP2020511940A5 (https=) | ||
| JP2007135598A (ja) | ポリエピトープワクチン | |
| HU222191B1 (hu) | Hiányos rekombináns adenovírusok termelésére alkalmas sejtvonal és eljárások ilyen vírusok termeltetésére | |
| JP7092663B2 (ja) | 組換えオルフウイルスベクター | |
| JP2022513326A5 (https=) | ||
| JP7818587B2 (ja) | 組換えｈｖｔ及びその使用 | |
| WO2015024484A1 (zh) | 一种新型狂犬病疫苗及其制备方法 | |
| JP2005509420A5 (https=) | ||
| Tartaglia et al. | Vaccinia virus rifampicin-resistance locus specifies a late 63,000 Da gene product | |
| JPWO2019217922A5 (https=) | ||
| Yuan et al. | Direct cloning of a herpesvirus genome for rapid generation of infectious BAC clones | |
| JPWO2020243719A5 (https=) | ||
| Marsland et al. | Construction of a recombinant orf virus that expresses an Echinococcus granulosus vaccine antigen from a novel genomic insertion site | |
| Strive et al. | Development of canine herpesvirus based antifertility vaccines for foxes using bacterial artificial chromosomes | |
| EP0994958A2 (en) | Selective regulation of adenovirus production | |
| US5279965A (en) | Recombinant infectious laryngotracheitis virus | |
| Yll-Pico et al. | Highly stable and immunogenic CMV T cell vaccine candidate developed using a synthetic MVA platform | |
| JPS615786A (ja) | 単純ヘルペスウイルス遺伝子を組込んだ組換えｄｎａ、形質転換動物細胞および単純ヘルペスウイルス蛋白質の製法 | |
| EP0353809A1 (en) | Pseudorabies virus vaccine | |
| JPH03504196A (ja) | 新規組換えワクチニアウイルス発現ベクター及びその選択方法 |